PET radioligands for the dopamine D1-receptor: Application in psychiatric disorders.
D1
Depression
Dopamine
PET
Schizophrenia
Substance use disorder
Journal
Neuroscience letters
ISSN: 1872-7972
Titre abrégé: Neurosci Lett
Pays: Ireland
ID NLM: 7600130
Informations de publication
Date de publication:
19 01 2019
19 01 2019
Historique:
received:
02
12
2017
revised:
06
02
2018
accepted:
03
03
2018
pubmed:
9
3
2018
medline:
25
7
2019
entrez:
9
3
2018
Statut:
ppublish
Résumé
The dopamine (DA) system is considered to be centrally involved in the pathophysiology of several major psychiatric disorders. Using positron emission tomography (PET), aberrations in dopamine D2/D3-receptors (D2-R) levels and uptake of the DA precursor FDOPA have been shown for schizophrenia, substance abuse and depression. Radioligands for the dopamine D1-receptor (D1-R) have been available for more than three decades, however this receptor subtype has received much less attention in psychiatry research. Here, studies investigating D1-R in psychiatric patients in comparison to healthy control subjects are summarized. Although small sample sizes, medication effects and heterogeneous methods of quantification limit the conclusions that can be drawn, the data is suggestive of higher levels of cortical D1-R in drug naïve patients with psychosis, and lower D1-R in patients with affective disorders. Data sharing and reanalysis using harmonized methodology are important next steps towards clarifying the role of D1-R in these disorders.
Identifiants
pubmed: 29518542
pii: S0304-3940(18)30176-9
doi: 10.1016/j.neulet.2018.03.007
pii:
doi:
Substances chimiques
DRD1 protein, human
0
DRD2 protein, human
0
DRD3 protein, human
0
Receptors, Dopamine D1
0
Receptors, Dopamine D2
0
Receptors, Dopamine D3
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Pagination
26-34Informations de copyright
Copyright © 2018 The Author(s). Published by Elsevier B.V. All rights reserved.